Last reviewed · How we verify
Dipeptidyl peptidase-4 inhibitors
Dipeptidyl peptidase-4 inhibitors is a DPP-4 inhibitor Small molecule drug developed by Ain Shams University. It is currently in Phase 3 development for Type 2 diabetes mellitus.
Dipeptidyl peptidase-4 inhibitors block the DPP-4 enzyme, which normally inactivates incretin hormones, thereby prolonging GLP-1 and GIP signaling to increase insulin secretion and lower blood glucose.
Dipeptidyl peptidase-4 inhibitors block the DPP-4 enzyme, which normally inactivates incretin hormones, thereby prolonging GLP-1 and GIP signaling to increase insulin secretion and lower blood glucose. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Dipeptidyl peptidase-4 inhibitors |
|---|---|
| Sponsor | Ain Shams University |
| Drug class | DPP-4 inhibitor |
| Target | Dipeptidyl peptidase-4 (DPP-4) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
DPP-4 inhibitors work by inhibiting the dipeptidyl peptidase-4 enzyme that degrades incretin hormones (GLP-1 and GIP). By preventing this degradation, these drugs extend the half-life of active incretin hormones, which stimulate glucose-dependent insulin secretion from pancreatic beta cells and suppress glucagon release. This mechanism results in improved glycemic control with a low risk of hypoglycemia.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nasopharyngitis
- Headache
- Upper respiratory tract infection
- Pancreatitis
Key clinical trials
- Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC (PHASE4)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. (PHASE4)
- A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (PHASE4)
- Comparative Effectiveness of Empagliflozin in the US
- A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes (PHASE3)
- Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus (PHASE1, PHASE2)
- Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dipeptidyl peptidase-4 inhibitors CI brief — competitive landscape report
- Dipeptidyl peptidase-4 inhibitors updates RSS · CI watch RSS
- Ain Shams University portfolio CI
Frequently asked questions about Dipeptidyl peptidase-4 inhibitors
What is Dipeptidyl peptidase-4 inhibitors?
How does Dipeptidyl peptidase-4 inhibitors work?
What is Dipeptidyl peptidase-4 inhibitors used for?
Who makes Dipeptidyl peptidase-4 inhibitors?
What drug class is Dipeptidyl peptidase-4 inhibitors in?
What development phase is Dipeptidyl peptidase-4 inhibitors in?
What are the side effects of Dipeptidyl peptidase-4 inhibitors?
What does Dipeptidyl peptidase-4 inhibitors target?
Related
- Drug class: All DPP-4 inhibitor drugs
- Target: All drugs targeting Dipeptidyl peptidase-4 (DPP-4)
- Manufacturer: Ain Shams University — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus